Assay News and Research

RSS

Characterizing SARS-CoV-2 convalescent plasma

A new study published on the preprint server bioRxiv in June 2020 uses serologic correlates to assess the efficacy of convalescent plasma. This will also help to classify donor plasma as more or less potent at neutralizing the virus.

23 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

As problems grow with Abbott’s fast COVID test, FDA standards are under fire

In mid-May, the Food and Drug Administration issued a rare public warning about an Abbott Laboratories COVID-19 test that for weeks had received high praise from the White House because of its speed: Test results could be wrong.

22 Jun 2020

A highly sensitive and specific antibody test for COVID-19

A new proof-of-concept study by UK researchers, currently available on the medRxiv* preprint server, describes the development of an enzyme-linked immunosorbent assay that can be used when lower levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific-antibodies are present in serum and saliva samples.

21 Jun 2020

New technology detects breast cancer using tears

Kobe University and System Instruments Co., Ltd. researchers have developed TearExo; new technology to detect breast cancer using the exosomes found in tears as biomarkers. Exosomes are a subtype of extracellular vesicles.

19 Jun 2020

Characterizing "re-positives" in recovered COVID-19 patients

The novel coronavirus pandemic has been spreading silently or explosively in almost every country of the world, causing almost half a million deaths and nearly 8.5 million reported cases in just six months. While much is known about the virus and the illness by now, far more remains unclear. One such is the prevalence and persistence of antiviral immunity following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

19 Jun 2020

Researchers develop tool to identify proteins associated with drug side effects

A multi-institutional group of researchers led by Harvard Medical School and the Novartis Institutes for BioMedical Research has created an open-source machine learning tool that identifies proteins associated with drug side effects.

18 Jun 2020

New test will help better manage patients with severe combined immunodeficiency

A new test developed at CHU Sainte-Justine in Montreal will enable better management of patients with severe combined immunodeficiency.

17 Jun 2020

Novel ACE2-antibody fusion molecules show anti-SARS-CoV-2 activity

Now, in a new study published on the preprint server, bioRxiv researchers in the U.S. investigated a soluble version of ACE2 for SARS-CoV-2 viral neutralization activity.

17 Jun 2020

Severity of COVID-19 linked to heparanase activity and heparan sulfate levels

Researchers at Radboud University Medical Center in the Netherlands reported an increase of heparanase activity and heparan sulfate levels in the plasma of patients with coronavirus disease (COVID-19), which was also associated with the severity of the condition – suggesting, in turn, potential treatment utility of low molecular weight heparins. The paper is currently available on the medRxiv* preprint server.

16 Jun 2020

Study reports structure of enzyme activator for high pathogenic avian influenza

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the current pandemic of COVID-19, is the focus of many investigators seeking to find an effective vaccine or therapeutic. Among the potential targets are various protease enzymes suspected of allowing the virus to gain entry to host cells and establish a successful infection.

16 Jun 2020

SARS-CoV-2 mutation reduces S1 shedding, increases infective potential

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh coronavirus known to infect humans. SARS-CoV-2 emerged in the last month of 2019 in Wuhan, China, sparking off the ongoing COVID-19 pandemic. This virus enters the host cells through receptor binding and membrane fusion between the viral and host cell membrane.

16 Jun 2020

Testing reveals 11 percent of people in Geneva infected with SARS-CoV-2

Now, a team of researchers at Geneva University Hospitals has found that less than 11 percent of the population in Geneva has contracted the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their research is published in the journal The Lancet.

15 Jun 2020

Nasal swab tests miss low viral SARS-CoV-2

A recent study by researchers from Beth Israel Deaconess Medical Center and Harvard Medical School, currently available on the preprint server medRxiv, demonstrates how nasal swab samples reliably detect patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that present with high viral loads, but may miss many patients with lower viral loads – questioning their role as a sole specimen for diagnostic purposes.

15 Jun 2020

Chimeric reference standards for validating controls in SARS-CoV-2 tests

A preliminary study by researchers from the Garvan Institute of Medical Research and the University of New South Wales and published on the preprint server bioRxiv in June 2020 reports the use of chimeric design to produced reference standards for diagnostic tests. This could allow a highly flexible approach to the development of different genetic features in the same test, even for organisms that are not directly related.

15 Jun 2020

An entire trimeric S-protein of SARS-CoV-2 is necessary for protective immune response

Researchers from Seattle Children's Research Institute and the University of Washington described a high-throughput and rapid technique to quantify circulating levels of functional antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the entire viral spike protein should be used to characterize the immune response. Their paper is currently available on the medRxiv* preprint server.

14 Jun 2020

Early neutralizing response to SARS-CoV-2 dominated by IgA antibodies

Researchers from France and the U.S. demonstrated how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection could induce an early and vigorous virus-specific IgA response that paves the way for the production of SARS-CoV-2 IgG antibodies, with even better neutralizing properties. Their paper is currently available on the medRxiv preprint server.

14 Jun 2020

Cannabis plant may harbor SARS-CoV-2 for at least a week

Researchers at the Medicinal Genomics Corporation have warned that cannabis flowers exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may harbor the virus for at least seven days.

14 Jun 2020

NIAID and Moderna scientists describe SARS-CoV-2 vaccine development

Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.

14 Jun 2020